Orlando location establishes key presence in major population center in Florida

The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical development and focused on advancing Kadimastem's allogeneic cell therapy platform

Each of Kadimastem and NLS Pharmaceutics has received commitments of support for the transaction from shareholders representing more than 40% of their respective outstanding shares

CyttaCOMMS In Active Trials With 54 Florida Law Enforcement Agencies With Over 600 Florida Direct Demo Requests Outstanding

ARIA Cybersecurity asked to update the industry on cybersecurity risk measurement and attack defense strategies